3Jonas S, Sugimori M, Llinas R. Is low molecular weight heparon a neuroprotectant?Ann N Y Aced Sci, 1997,825: 389
4Li PA, He QP, Siddiqui MM, et al, Posttreatment with low molecular weiht heparin reduces brain edema and infarct volume in sats subjected to thrombotic middle cerebral arteryu occlusion. Brain Res, 1998,801(1-2):220
5Baram D, Rashkovsky M, Hershkoviz R, et al. Inhibitory errects of low molecular weighthepann on mediator release by mast cells: preferentoal inhibition of cytokine production and mast cell - dependent cutaneous iotlammation. Clin Expimmunol 1997,110(3)485
6Schwattz D, Egelhatd D, Gallil R, et al, Glial cells producton of inflammatory mediators induced by Streptococcus pneumoniae: inhilion by pentoaifine,low - moleeular- weight heparin heparin and dexamethasone. J Neurol sci, 1998,155( 1 ): 13
7Estol CJ. Anticoagulants: which, how much, until when: these are still questions Ⅱ . Rev Neuro l, 1999,29 (12): 1190
8Munoz Torrero J J, Diez Tejedor E. Anticoagulation and antiaggregation:implication in the actute phase of stroke following IST, CAST,TOAST,FISS and FIS bis. Rev Neurol, 1999,29(8) :769
9Bijsterveld NR Hettiarachchi R, et al Low- molecular weight heparin in venous and arterial thrombotic disease. Thromb Haemost, 1999,82(suppl Ⅰ):139
10Kay R, Wong KS, Yu YL, et al, Low- molecular weight heparin for the treatment of acute ischemic stroke. N Engl J Med, 1995,333(24): 1588
二级参考文献1
1V.V. Kakkar,O. Boeckl,B. Boneu,L. Bordenave,O.A. Brehm,Peter Brücke,S. Coccheri,A.T. Cohen,F. Galland,S. Haas,J. Jarrige,K. Koppenhagen,A. LeQuerrec,E. Parraguette,P. Prandoni,J.D. Roder,M. Roos,C. Rüschemeyer,J.R. Siewert,H. Vinazzer,E. Wenzel. Efficacy and Safety of a Low-Molecular-Weight Heparin and Standard Unfractionated Heparin for Prophylaxis of Postoperative Venous Thromboembolism: European Multicenter Trial[J] 1997,World Journal of Surgery(1):2～9
